Washington, D.C.— Congressman Tom Marino (R-PA-10) issued the following statement after requesting that President Donald Trump withdraw his name from consideration to lead the Office of National Drug Control Policy (ONDCP):
“Today I informed President Donald Trump of my intent to withdraw my name from any further consideration to lead ONDCP.
“As a former prosecutor who has dedicated my life to aggressive and faithful enforcement of our laws, I have reached the difficult decision that the best course of action is to remove the distraction my nomination has created to the utterly vital mission of this premier agency.
“At the same time, given my lifelong devotion to law enforcement, I insist on correcting the record regarding the false accusations and unfair reporting to which I have been subjected.
“I’m proud of my work on the Ensuring Patient Access and Effective Drug Enforcement Act of 2016, which passed with unanimous consent in the House and Senate, unopposed by the DEA and was signed into law by President Obama. This landmark legislation will help to facilitate a balanced solution for ensuring those who genuinely needed access to certain medications were able to do so, while also empowering the Drug Enforcement Agency (DEA) to enforce the law and prevent the sale and abuse of prescription drugs.
“Given these facts and the importance of this legislation, I find it sad and disheartening that the news media have left behind any concept of balanced reporting and credited conspiracy theories from individuals seeking to avert blame from their own failures to address the opioid crisis that proliferated during their tenure. Specifically, I cannot allow false allegations made by a former DEA employee, who resigned from the agency. He was the subject of a professional conduct investigation and his assertions may be motivated by financial self-interest, to overshadow the real problems with prescription drug abuse in this country.
“I will continue to support President Trump in his mission to get the people’s government back to working in their best interests – not those who seek to maintain the status quo.
“I look forward to remaining in service to the people of Pennsylvania’s Tenth Congressional District and continuing my long record of championing solutions to better equip law enforcement to combat drugs.”Read More
Washington, D.C.—Tomorrow at 1:00 p.m. Congressman Tom Marino (PA-10) will hold a hearing on anticompetitive behavior and the health care marketplace. The hearing in the House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law, of which Marino is the Chairman, is titled “Antitrust Concerns and the FDA Approval Process.” Two panels of witnesses will testify on competition issues for the pharmaceutical industry and how these anticompetitive practices have harmful effects on patients.
Chairman Marino issued the following statement:
“I am very pleased to be holding this hearing and am eager to hear from the distinguished witnesses regarding the issues around drug competition. I am particularly interested in hearing testimony from Dr. Scott Gottlieb, the Commissioner of the FDA, as he has made drug pricing and competition in the pharmaceutical marketplace a cornerstone early in his tenure.”
"I constantly hear from my constituents about how the pharmaceutical drug market is unfair and prices are too high. This is why earlier this year Ranking Member Cicilline and I introduced H.R. 2212, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act to address anticompetitive concerns associated with the FDA’s Risk Evaluation and Mitigation Strategy, or REMS Program. The CREATES Act addresses an issue that Commissioner Gottlieb has identified himself, that pharmaceutical companies are blocking more affordable generic alternatives from coming to the market. I hope to hear more from Commissioner Gottlieb, and the rest of the witnesses, on the abuses that are involved in the REMS Program and other ways patients lose on account of these and other anticompetitive practices.”Read More
Washington, D.C.--Today, the U.S. Food and Drug Administration (FDA) held a public meeting to solicit input in areas where the FDA’s rules are being used in ways that create obstacles and delays. FDA Commissioner Scott Gottlieb, M.D., has shown a commitment to ensuring that generic manufacturers have access to promote competition. Commissioner Gottlieb commented last week that the FDA has seen problems with branded pharmaceutical companies using the Risk Evaluation and Mitigation Strategy, or REMS Program, to block generic companies from gaining access to samples, which may delay the entry of safe and effective generic drugs onto the market.
On April 27, 2017, Representatives Tom Marino and David N. Cicilline, Chairman and Ranking Member, respectively, of the House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law, introduced H.R. 2212, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, to address anticompetitive conduct associated with the FDA’s REMS Program. The CREATES Act would deter pharmaceutical companies from blocking cheaper generic alternatives from the marketplace, a problem identified by Commissioner Gottlieb.
Chairman Marino and Ranking Member Cicilline issued the following statement:
“The CREATES Act will lead to lower costs for patients by ensuring they have access to generic medicines that have been approved by the FDA while closing regulatory loopholes that are used to keep prices artificially high. Patient safety will continue to be maintained by ensuring current safeguards. Our constituents have consistently contacted us to express their concerns with drug pricing and competition. The CREATES Act is a step in the right direction to ensure there is a greater choice of generics to bring drug costs down.”Read More
Washington, D.C. — Today, the House passed H.R. 2810, the National Defense Authorization Act (NDAA) for Fiscal Year 2018 by a bipartisan vote of 344-81. Rep. Tom Marino (PA-10) voted in favor of the legislation and released the following statement:
“We have the strongest military in the world and, in turn, we must provide the strongest support available to the men and women who put their lives on the line for our freedoms. It is unfair to expect our troops to perform at their highest capacity if they do not have the means to succeed.
“Our troops are our country’s most valuable asset and the 2.4% raise in salary is well deserved. It is important to remember that repairing and rebuilding our military is key to defending the country, therefore we must protect our brave servicemen and women.”
The NDAA for FY2018 authorizes a total of $631.5 billion for defense discretionary spending and an additional $64.6 billion in Overseas Contingency Operations (OCO) funding. In addition, the bill provides for an increase in active duty strength, adding 10,000 more personnel for the active duty Army, 4,000 more for the Navy, and 4,100 more for the Air Force while also funding a 2.4% pay raise for the troops.Read More
Washington D.C.—Congressman Tom Marino (PA-10) issued the following statement following the Trump administration’s withdrawal of the Waters of the United States rule, commonly referred to as WOTUS.
“I applaud the Trump administration’s decision to withdraw the Waters of the United States regulation. This was an egregious overreach by the EPA and the Army Corps of Engineers that would have expanded the agencies’ power to impose restrictions over waters and lands used by farmers, ranchers and landowners. The EPA already has extremely expansive and invasive powers, the last thing we need is another over expansive regulation. The Federal Government should leave the regulation of the states to the states, Pennsylvania knows best how to protect its environment and waters.”Read More
Washington, D.C. -- Congressman Tom Marino (PA-10) and Congressman John Lewis (GA-05) reintroduced H.R. 2644, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2017. This bill is aimed at improving the lives of those suffering with kidney disease by identifying barriers for transplantation and improving donation rates. It also allows individuals with kidney failure the ability to retain access to private insurance and promotes access to home dialysis treatments. Additionally, H.R. 2644 seeks to understand the progression of kidney disease and the treatment of kidney failure in minority populations and improve access to kidney disease treatment for those in underserved rural and urban areas.
Congressman Marino said the following regarding the introduction of this bill:
“I would like to thank my colleagues John Lewis and Peter Roskam for continuing to support our efforts to bring an end to Kidney disease and make access to breakthrough treatments easier to obtain for those suffering with this disease. Kidney disease has touched the lives of millions of American, including myself, and this bill is a step in the right direction to better understand the disease and find a cure.”
Congressman Lewis said the following:
“I am proud to introduce legislation with my colleague Tom Marino that has the power to ease the strain of kidney disease on patients and families. Kidney disease is a debilitating medical condition that dramatically changes the lives of those who suffer from it. Anything that we can do as the people’s representatives to help patients and families living with kidney disorders is our duty and obligation. All the answers we need will not come from one legislative solution, but if we are persistent and consistent we can chip away at the obstacles this disease creates and one day find a cure.”
Washington D.C. – Today, Congressman Tom Marino (PA-10) and Congressman James P. McGovern (MA-02), co-chairs of the Congressional Cystic Fibrosis Caucus, introduced H.Con.Res. 58, a bipartisan resolution to recognize May as Cystic Fibrosis Awareness Month. This resolution recognizes the Cystic Fibrosis community for their dedication to their patients, acknowledges the investments and scientific achievements that have improved patients’ lives, and urges researchers, developers, patients, and providers to do everything possible to find a cure for this deadly disease.
Congressman Marino released the following statement:
“I am pleased to join my colleague in introducing H.Con.Res. 58 to recognize May as Cystic Fibrosis Awareness Month. My daughter Chloe lives with Cystic Fibrosis and I have done everything I can to make sure she receives the best care possible so she can live a long and prosperous life. I hope that by bringing awareness to Cystic Fibrosis we can find a cure for not only this disease but all other rare diseases.”
Congressman McGovern said the following:
“Cystic Fibrosis is a rare genetic disease that affects 30,000 children and adults in the United States. I am proud to support this resolution to bring awareness and recognition to the Cystic Fibrosis community and continue the medical advancements that will improve the quality of life and life expectancy for those living with CF.”Read More
Washington D.C. – Today the U.S. House of Representatives passed H.R.1628, the American Health Care Act (AHCA) by a vote of 217-213. Congressman Tom Marino (PA-10) issued the following statement in support of the bill:
“When I was elected in 2010, I made a promise to my constituents that I would work to repeal and replace Obamacare. Today, I am happy to announce that I have fulfilled that promise by voting with my colleagues in the House to pass the American Health Care Act.
“For six years, Obamacare has failed the American people. I have been a vocal leader in efforts to repeal this failed health care law. The AHCA is a vast improvement over Obamacare and it will give the American people the freedom to choose their own health care.”
“The AHCA will lower premiums that have been crushing our families and business owners, reduce an out of control deficit by $337 billion, and provide tax relief for our middle class families by eliminating the individual mandate. The AHCA also makes major entitlement reform by capping Medicaid spending for the first time, empowering the states and saving taxpayers nearly $840 billion.
“As a three time cancer survivor, and the father of someone living with Cystic Fibrosis, I am proud to vote for a bill that continues to protect the most vulnerable Americans. The AHCA ensures no one can be denied coverage based on pre-existing conditions, and prohibits lifetime limits on coverage. Additionally, the ACHA provides states with $100 billion to design programs that meet the unique needs of their patient populations and provides an additional $15 billion for mental health and substance abuse disorders.”Read More
Washington D.C. – Rep. Tom Marino (PA-10) released the following statement on possible appointment as Director of the Office of National Drug Control Policy (ONDCP), commonly known as the Drug Czar:
“Due to a critical illness in my family, I have, with regret and the utmost respect, informed the White House that I must withdraw my name from consideration for Director of the Office of National Drug Control Policy. I thank the President for the enormous honor of considering me for this lead role in the effort to address one of the most pressing issues facing our nation and my state today: the opioid epidemic. I will remain in Congress and continue to support President Trump in whatever way I can.”
Washington, D.C. – Today, top leaders on the Senate and House Judiciary Committees led by Senator Patrick Leahy (D-VT) introduced legislation to combat anticompetitive practices used by some brand-name pharmaceutical and biologic companies to block entry of lower-cost generic drugs. The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act would deter pharmaceutical companies from blocking cheaper generic alternatives from entering the marketplace. The bill is sponsored by Leahy and cosponsored by Chairman Chuck Grassley (R-IA) Ranking Member Dianne Feinstein (D-CA) and by Senators Amy Klobuchar (D-MN) and Mike Lee (R-UT) leaders of the Subcommittee on Antitrust, Competition Policy and Consumer Rights. Lead sponsor, Representative Tom Marino (PA-10) and Representative David Cicilline (RI-1), Chairman and Ranking Member, respectively, of the House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law, introduced an identical version of the bill in the House.
Leahy said: “Vermonters and American families across the nation know from hard experience that many prescription drugs are simply too expensive. Vermonters tell me that the high cost of prescription drugs has become their top health care concern. When brand companies can drive up the price of drugs through predatory practices, patients suffer. Illnesses worsen. Families, government programs, and other payers in the healthcare system ultimately bear those added, unnecessary costs. Strategies wielded by these firms to delay entry of lower cost generic drugs are wrong, and they cause real harm. Drug affordability is a bipartisan issue that affects every American. This needs to be a high priority. I’m committed to working on behalf of Vermonters to see that the CREATES Act and other vital initiatives to address the high cost of prescription drugs are signed into law.”
“I frequently hear from Iowans about the high price of prescription drugs. Many Americans rely on more affordable generic medications once patents have expired for brand-name drugs,” Grassley said. “Unfortunately, we’re seeing some brand-name drug companies engage in anti-competitive tactics that delay entry of lower cost generic drugs into the market. This bill takes important steps to improve the current system so that consumers have access to less expensive generic drugs in a timely fashion.”
“When people get sick, their focus should be on getting well, not on how to pay for their prescriptions,” Klobuchar said. “Our bipartisan legislation would put an end to pharmaceutical company tactics that delay or prevent lower-cost competition while protecting patient safety and saving Americans consumers billions of dollars.”
"Nearly everyone has a story about sticker shock at the pharmacy counter or anger at learning the drug they need isn’t covered by their health insurance,” Lee said. “Unfortunately, complex regulatory environments are being abused by some firms to avoid competition and keep prices high. Our CREATES Act aims to curb such regulatory abuse and facilitate generic entry, thereby lowering prices and increasing access while maintaining safety levels.”
Feinstein said: “The rapidly rising cost of prescription drugs, particularly those for cancer and chronic diseases, places a huge financial burden on patients and families nationwide. Ensuring generic drugs can get to market is one way to address this problem. Our bill would help put a stop to the unfair practices that block generic drugs from the market by giving companies legal avenues to challenge them.”
"As seniors struggle to pay for prescription drugs, pharmaceutical companies are raising the cost of drugs and making huge profits off of our nation’s most vulnerable populations. Speeding the entry of affordable and safe generic drugs into the market is a national priority that will lower prices through increased competition," said Cicilline. "The CREATES Act is a vital step in achieving this goal. By ending regulatory evasion and manipulation of safety protections through a well-tailored and cost-saving remedy, the CREATES Act will increase the number of affordable generic choices for consumers in the prescription drug market."
Marino said: “The CREATES Act will lead to lower costs for patients by ensuring that they have access to safe and effective FDA approved generic medicines. It will also ensure consumer safety by maintaining safeguard features of the Risk Evaluation and Mitigation Strategies (REMS) Program while closing regulatory loopholes that are used to keep prices artificially high.”
The Congressional Budget Office has estimated that the bill would result in a $3.3 billion net decrease in the federal deficit. Savings to consumers and private insurers likely would be far greater.
The legislation, a version of which was introduced in the House earlier this year, is strongly supported by the Association for Accessible Medicines (AAM), consumer groups including AARP, Consumers Union, and Public Citizen; the American College of Physicians; the American Hospital Association; the Campaign for Sustainable Rx Pricing; and America’s Health Insurance Plans (AHIP).Read More
410 Cannon HOB
Washington, DC 20515
Tom Marino came to Congress in January 2011 in much the same way he arrived at other destinations throughout this life: with a sense of purpose, a clear set of goals, and a common-sense approach to finding solution to serious problems.
Though he had previously talked about running for Congress, it wasn’t until he found himself so frustrated by the direction the nation was taking that he declared himself a candidate in early 2010.
He emerged the victor of a three-man Republican primary race and went on to defeat two-term Democrat incumbent Chris Carney by 10 percentage points in November 2010.
With his two children at his side, he was sworn into the U.S. House of Representatives on January 5, 2011, becoming part of the largest freshman class in decades.
Tom was re-elected to serve a second term in 2012, receiving 66 percent of the vote in the general election.
Marino maintained his standing on three House committees – Foreign Affairs, Homeland Security, and the Judiciary – and six subcommittees, two of which he serves as Vice Chairman.
The assignments are a good fit for the attorney who gained a reputation as a tough prosecutor, first as Lycoming County District Attorney and then as U.S. Attorney for the Middle District of Pennsylvania.
But when Congressman Marino tells working people that he knows where they are coming from, he means it.
That’s because he is never far from his blue-collar roots and the middle-class Williamsport neighborhood home where his mother still lives.
Tom, one of four children to Vivian Marino and the late Joseph Marino, is a second-generation Italian-American. His father was a janitor and a fireman and his mother was a homemaker.
Tom married his high school sweetheart, Edie, and went to work in the manufacturing field. It wasn’t until he was passed over for a promotion that he realized the importance of a college education.
So, at 30 years old, Tom sold his truck and Edie worked full time as he enrolled in college. Tom earned his bachelor’s and law degrees in five years, attending the former Williamsport Area Community College, Lycoming College and Dickinson School of Law.
He practiced law for several years before being elected to two terms as District Attorney for Lycoming County. He later served as U.S. Attorney for the Middle District of Pennsylvania, where his name became synonymous with cracking down on organized crime and drug trafficking. He was the first U.S. Attorney to attend the Top Gun PA X training classes and completed a National Security Seminar at the U.S. Army War College at the Carlisle Barracks.
Tom returned to work as a private-practice attorney for two years before deciding to run for Congress.
Tom and Edie have two adopted children, Chloe and Victor, and live in Cogan Station, Lycoming County.
A three-time cancer survivor, Tom is active in community events and enjoys reading, motorcycle riding, weightlifting, running, and spending time with his family.
Besides his committee work, Tom is involved with a number of congressional caucuses, and serves as Co-Chairman of the Cystic Fibrosis Caucus, Congressional Kidney Caucus, and the Congressional Caucus on Foster Youth.
Retweeted by reptommarino
I urge my colleagues in the House to join us in safeguarding the health of Americans with kidney disease.https://t.co/M1QsiUe209
Retweeted by reptommarino
This Kidney disease bill is a step in the right direction to better understand this disease and find a cure. https://t.co/tNFlHROi0l
Retweeted by reptommarino
We must continue to help our foster care system thrive. #ShadowDay
Retweeted by reptommarino
I hope by bringing awareness to Cystic Fibrosis we can find a cure for not only this disease but all rare diseases. https://t.co/cFauHIJlX1